Advertisement

Drugs

pp 1–10 | Cite as

Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease

  • Samarth Siddharth Patel
  • Mohammad Shadab Siddiqui
Review Article
  • 116 Downloads

Abstract

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the developed world and commonly associated with metabolic comorbidities such as diabetes mellitus, hypertension, dyslipidemia, and obesity. Non-alcoholic steatohepatitis is an aggressive form of non-alcoholic fatty liver disease, associated with an increased risk of liver and non-liver-related mortality. Currently there are no approved therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and standard-of-care lifestyle advice is rarely effective. This has spurned intense drug development efforts and several agents are in clinical trials to address this major gap in non-alcoholic fatty liver disease. Drug development efforts have focused on pathogenic mechanisms including pathways involving lipid metabolism, inflammation, and fibrosis. This review presents the overview of the trials and agents in the pipeline of emerging therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

Notes

Compliance with Ethical Standards

Funding

No funding/financial support was received for the conduct of this research or for the preparation of this article.

Conflict of interest

Samarth S. Patel and Mohammad Shadab Siddiqui have no conflicts of interest that are directly relevant to the contents of this article.

References

  1. 1.
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–30 (quiz e60).PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–86.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017–23.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367.e5–378.e5 (quiz e14–15).Google Scholar
  9. 9.
    Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–88 (quiz e15–16).PubMedCrossRefGoogle Scholar
  10. 10.
    Dudekula A, Rachakonda V, Shaik B, Behari J. Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS ONE. 2014;9:e111808.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Eng J Med. 2006;355:2297–307.CrossRefGoogle Scholar
  14. 14.
    Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology. 2008;135:100–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(389–97):e10.Google Scholar
  17. 17.
    Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stal P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Younossi ZM. Long-term outcomes of nonalcoholic fatty liver disease: from nonalcoholic steatohepatitis to nonalcoholic steatofibrosis. Clin Gastroenterol Hepatol. 2017;15:1144–7.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(1147–59):e5.Google Scholar
  20. 20.
    Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–65.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344–53.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357–65.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Wong VW-S, Wong GL-H, Yip GW-K, Lo AO-S, Lim J, Chu WC-W, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut. 2011;60:1721–7.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with monalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus. Ann Intern Med. 2016;165:305.PubMedCrossRefGoogle Scholar
  25. 25.
    Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67:1754–67.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedCrossRefGoogle Scholar
  28. 28.
    Keating SE, Hackett DA, Parker HM, O’Connor HT, Gerofi JA, Sainsbury A, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol. 2015;63:174–82.PubMedCrossRefGoogle Scholar
  29. 29.
    Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235–42.PubMedCrossRefGoogle Scholar
  30. 30.
    Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49:80–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Després J-P, Ross R, Boka G, Alméras N, Lemieux I, ADAGIO-Lipids Investigators. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol. 2009;29:416–23.PubMedCrossRefGoogle Scholar
  32. 32.
    Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706–13.PubMedCrossRefGoogle Scholar
  33. 33.
    Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol. 2003;12:189–92.PubMedGoogle Scholar
  34. 34.
    James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17.PubMedCrossRefGoogle Scholar
  35. 35.
    Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–92.PubMedCrossRefGoogle Scholar
  37. 37.
    Siddiqui MS, Cheang KL, Luketic VA, Boyett S, Idowu MO, Patidar K, et al. Nonalcoholic steatohepatitis (NASH) is associated with a decline in pancreatic beta cell (β-cell) function. Dig Dis Sci. 2015;60:2529–37.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893–4.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009;29:172–82.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100:1082–90.PubMedCrossRefGoogle Scholar
  41. 41.
    Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–68.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99:2416–22.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial. Hepatology. 2010;51:445–53.PubMedCrossRefGoogle Scholar
  44. 44.
    Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMedCrossRefGoogle Scholar
  45. 45.
    Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Bril F, Kalavalapalli S, Clark VC, Lomonaco R, Soldevila-Pico C, Liu I-C, et al. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018;16(558–66):e2.Google Scholar
  47. 47.
    Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349–54.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother. 2007;41:2014–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43:993–1002.PubMedCrossRefGoogle Scholar
  51. 51.
    Alam S, Kabir J, Mustafa G, Gupta U, Hasan SKMN, Alam AKMK. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: a 1-year randomized control trial. Saudi J Gastroenterol. 2016;22:69–76.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M, et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013;2013:587140.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–13.PubMedCrossRefGoogle Scholar
  55. 55.
    Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, et al. Sitagliptin versus placebo in the treatment of nonalcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016;65:369–76.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941–52.PubMedCrossRefGoogle Scholar
  57. 57.
    Poulsen LI, Siersbæk M, Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol. 2012;23:631–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–44.PubMedCrossRefGoogle Scholar
  59. 59.
    Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113:1408–18.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, Kasmi KE, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem. 2013;288:11761–70.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1:1024–42.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;391:1174–85.PubMedCrossRefGoogle Scholar
  63. 63.
    Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004;2:1107–15.PubMedCrossRefGoogle Scholar
  64. 64.
    Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012;56:1311–8.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–65.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549–56.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.PubMedCrossRefGoogle Scholar
  69. 69.
    Beilfuss A, Sowa J-P, Sydor S, Beste M, Bechmann LP, Schlattjan M, et al. Vitamin D counteracts fibrogenic TGF-β signalling in human hepatic stellate cells both receptor-dependently and independently. Gut. 2015;64:791–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology. 2012;56:2180–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485–90.PubMedCrossRefGoogle Scholar
  72. 72.
    Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis: a randomized and controlled clinical trial. Am J Gastroenterol. 2010;105:1338–45.PubMedCrossRefGoogle Scholar
  73. 73.
    Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Digest Liver Dis. 2008;40:194–9.CrossRefGoogle Scholar
  74. 74.
    Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50:1102–11.PubMedCrossRefGoogle Scholar
  75. 75.
    Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol. 2013;5:109–13.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA. Functions of coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr. 2016;35:346–53.PubMedCrossRefGoogle Scholar
  77. 77.
    Chang X, Wang Z, Zhang J, Yan H, Bian H, Xia M, et al. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med. 2016;14:266.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul M-C, Iannelli A, et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One. 2010;5:e13577.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Seki E, De Minicis S, Inokuchi S, Taura K, Miyai K, Van Rooijen N, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009;50:185–97.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11:e0158156.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Yamamoto E, Dong Y-F, Kataoka K, Yamashita T, Tokutomi Y, Matsuba S, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension. 2008;52:573–80.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Wang P-X, Ji Y-X, Zhang X-J, Zhao L-P, Yan Z-Z, Zhang P, et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med. 2017;23:439–49.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Budas G, Karnik S, Jonnson T, Shafizadeh T, Watkins S, Breckenridge D, et al. PS070: reduction of liver seatosis and fibrosis with an Ask1 inhibitor in a murine model of Nash is accompanied by improvements in cholesterol, bile acid and lipid metabolism. J Hepatol. 2016;64:S170.CrossRefGoogle Scholar
  84. 84.
    Reilly SM, Chiang S-H, Decker SJ, Chang L, Uhm M, Larsen MJ, et al. An inhibitor of the protein kinases TBK1/IKKε improves obesity-related metabolic dysfunctions. Nat Med. 2013;19:313–21.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2017.  https://doi.org/10.1002/hep.29514 (Epub ahead of print).CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Patel SS, Guzman L, Lin F-P, Pence T, Reichman T, John B, et al. Utilization of aspirin and statin in mnagement of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation. Liver Transpl. 2018;24(7):872–80.PubMedCrossRefGoogle Scholar
  87. 87.
    Kamal S, Khan MA, Seth A, Cholankeril G, Gupta D, Singh U, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol. 2017;112:1495–505.PubMedCrossRefGoogle Scholar
  88. 88.
    Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metab, Clin Exp. 2008;57:1711–8.CrossRefGoogle Scholar
  89. 89.
    Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21:7860–8.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–4.PubMedCrossRefGoogle Scholar
  91. 91.
    Mauro VF, Tuckerman CE. Ezetimibe for management of hypercholesterolemia. Ann Pharmacother. 2003;37:839–48.PubMedCrossRefGoogle Scholar
  92. 92.
    Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007;581:5664–70.PubMedCrossRefGoogle Scholar
  93. 93.
    Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:101–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61:1239–50.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Zhang MJ, Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Annu Rev Nutr. 2012;32:203–27.PubMedCrossRefGoogle Scholar
  96. 96.
    Schmitz G, Ecker J. The opposing effects of n − 3 and n − 6 fatty acids. Prog Lipid Res. 2008;47:147–55.PubMedCrossRefGoogle Scholar
  97. 97.
    Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147(377–84):e1.Google Scholar
  98. 98.
    Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–87.PubMedCrossRefGoogle Scholar
  99. 99.
    Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412–25.PubMedCrossRefGoogle Scholar
  100. 100.
    Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206–11.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012;142(1100–1):e2.Google Scholar
  102. 102.
    Adar T, Ben Ya'acov A, Lalazar G, Lichtenstein Y, Nahman D, Mizrahi M, et al. Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol. 2012;167:252–60.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Mizrahi M, Shabat Y, Ya’acov BA, Lalazar G, Adar T, Wong V, et al. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res. 2012;5:141–50.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(2085–91):e1.Google Scholar
  105. 105.
    ClinicalTrials.gov. Phase 2a, dose-ranging study with PF-05221304 in nonalcoholic fatty liver disease (NAFLD). https://clinicaltrials.gov/ct2/show/NCT03248882.. Accessed 3 Sep 2018
  106. 106.
    ClinicalTrials.gov. GS-0976 in adults with nonalcoholic steatohepatitis. https://clinicaltrials.gov/ct2/show/NCT02856555.. Accessed 3 Sep 2018
  107. 107.
    Kim C-W, Addy C, Kusunoki J, Anderson NN, Deja S, Fu X, et al. Acetyl coA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab. 2017;26(394–406):e6.Google Scholar
  108. 108.
    Shiffman M, Freilich B, Vuppalanchi R, Watt K, Burgess G, Morris M, et al. LP37: a placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases. J Hepatol. 2015;62:S282.CrossRefGoogle Scholar
  109. 109.
    Linton SD, Aja T, Armstrong RA, Bai X, Chen L-S, Chen N, et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. J Med Chem. 2005;48:6779–82.PubMedCrossRefGoogle Scholar
  110. 110.
    Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35:953–66.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Frenette CT, Morelli G, Shiffman ML, Frederick RT, Rubin RA, Fallon MB, et al. Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo. Clin Gastroenterol Hepatol. 2018;18:432.  https://doi.org/10.1016/j.cgh.2018.06.012 (Epub ahead of print).CrossRefGoogle Scholar
  112. 112.
    ClinicalTrials.gov. Emricasan, a caspase inhibitor, for treatment of subjects with decompensated NASH cirrhosis. https://clinicaltrials.gov/ct2/show/NCT03205345.. Accessed 3 Sep 2018.
  113. 113.
    ClinicalTrials.gov. Emricasan, an oral caspase inhibitor, in subjects with non-alcoholic steatohepatitis (NASH) cirrhosis and severe portal hypertension. https://clinicaltrials.gov/ct2/show/NCT02960204.. Accessed 3 Sep 2018.
  114. 114.
    Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103:5060–5.PubMedCrossRefGoogle Scholar
  115. 115.
    Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel M-I, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One. 2013;8:e75361.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Harrison SA, Marri SR, Chalasani N, Kohli R, Aronstein W, Thompson GA, et al. Randomised clinical study. Aliment Pharmacol Ther. 2016;44:1183–98.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Samarth Siddharth Patel
    • 1
  • Mohammad Shadab Siddiqui
    • 1
  1. 1.Division of Gastroenterology, Hepatology and Nutrition, Department of Internal MedicineVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations